{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:45:01Z","timestamp":1790675101037,"version":"4.1.0"},"reference-count":43,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tissue inhibitor of metalloproteinase 1 (TIMP-1) is a stromal factor with multiple functions. Overexpression of TIMP-1 correlates with aggressive clinical behavior of a spectrum of tumors. Here, for the first time, we address the role of TIMP-1 in the pathogenesis of B-cell lymphomas. An Epstein-Barr virus (EBV)-negative Burkitt lymphoma cell line with ectopic TIMP-1 expression (TIMP-1JD38) was used to identify genes induced\/repressed by TIMP-1. Differentially expressed genes were analyzed by cDNA microarray, and they were validated by immunohistochemistry, flow cytometry, and Western blotting. Analysis revealed changes of genes coding for B-cell growth\/differentiation, transcription, and cell cycle regulators. TIMP-1 repressed expression of germinal center (GC) markers CD10, Bcl-6, PAX-5 and up-regulated plasma cell-associated antigens CD138, MUM-1\/IRF-4, XBP-1, and CD44, suggesting a plasma cell differentiation. This is accompanied by activation of signal transducer and activator of transcription 3 (STAT-3) and switch to cyclin D2 expression. However, TIMP-1JD38 cells expressed an inactive form of XBP-1, lacking antibody production\/secretion. This incomplete plasmacytic differentiation occurs without altering cell proliferation, and despite c-Myc deregulation, indicating an arrested plasmacytic\/plasmablastic stage of differentiation. Further validation in human lymphoma cell lines and in primary B-cell tumors demonstrated a predominant TIMP-1 expression in tumors with plasmacytic\/plasmablastic phenotypes, including multiple myelomas. These findings strongly support TIMP-1 as an important factor in the pathogenesis of plasmacytic\/plasmablastic tumors. (Blood. 2005;105:1660-1668)<\/jats:p>","DOI":"10.1182\/blood-2004-04-1385","type":"journal-article","created":{"date-parts":[[2004,10,13]],"date-time":"2004-10-13T01:32:57Z","timestamp":1097631177000},"page":"1660-1668","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":46,"title":["Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic\/plasmablastic tumors"],"prefix":"10.1182","volume":"105","author":[{"given":"Liliana","family":"Guedez","sequence":"first","affiliation":[{"name":"From the Cell and Cancer Biology Branch and Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD; and Department of Pathology, Hospital del Mar, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Martinez","sequence":"additional","affiliation":[{"name":"From the Cell and Cancer Biology Branch and Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD; and Department of Pathology, Hospital del Mar, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumei","family":"Zhao","sequence":"additional","affiliation":[{"name":"From the Cell and Cancer Biology Branch and Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD; and Department of Pathology, Hospital del Mar, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Vivero","sequence":"additional","affiliation":[{"name":"From the Cell and Cancer Biology Branch and Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD; and Department of Pathology, Hospital del Mar, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Pittaluga","sequence":"additional","affiliation":[{"name":"From the Cell and Cancer Biology Branch and Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD; and Department of Pathology, Hospital del Mar, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryalice","family":"Stetler-Stevenson","sequence":"additional","affiliation":[{"name":"From the Cell and Cancer Biology Branch and Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD; and Department of Pathology, Hospital del Mar, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Raffeld","sequence":"additional","affiliation":[{"name":"From the Cell and Cancer Biology Branch and Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD; and Department of Pathology, Hospital del Mar, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Stetler-Stevenson","sequence":"additional","affiliation":[{"name":"From the Cell and Cancer Biology Branch and Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD; and Department of Pathology, Hospital del Mar, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021217553959200_REF1","doi-asserted-by":"crossref","unstructured":"Guedez L, Lim MS, Stetler-Stevenson WG. The role of metalloproteinases and their inhibitors in hematological disorders. Crit Rev Oncog.1996;7: 205-225.","DOI":"10.1615\/CritRevOncog.v7.i3-4.40"},{"key":"2020021217553959200_","doi-asserted-by":"crossref","unstructured":"Nakopoulou L, Giannopoulou I, Stefanaki K, et al. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol.2002;197: 307-313.","DOI":"10.1002\/path.1129"},{"key":"2020021217553959200_REF3","doi-asserted-by":"crossref","unstructured":"Holten-Andersen MN, Murphy G, Nielsen HJ, et al. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer.1999;80: 495-503.","DOI":"10.1038\/sj.bjc.6690384"},{"key":"2020021217553959200_REF4","unstructured":"Zeng ZS, Cohen AM, Zhang ZF, Stetler-Stevenson W, Guillem JG. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res.1995;1: 899-906."},{"key":"2020021217553959200_REF5","unstructured":"Li G, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res.1999;59: 6267-627."},{"key":"2020021217553959200_REF6","doi-asserted-by":"crossref","unstructured":"Guedez L, Stetler-Stevenson WG, Wolff L, et al. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest.1998;102: 2002-2010.","DOI":"10.1172\/JCI2881"},{"key":"2020021217553959200_REF7","doi-asserted-by":"crossref","unstructured":"Thorns C, Gaiser T, Lange K, Merz H, Feller AC. cDNA arrays: gene expression profiles of Hodgkin's disease and anaplastic large cell lymphoma cell lines. Pathol Int.2002;52: 578-585.","DOI":"10.1046\/j.1320-5463.2002.01400.x"},{"key":"2020021217553959200_REF8","doi-asserted-by":"crossref","unstructured":"Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature.2000;403: 503-511.","DOI":"10.1038\/35000501"},{"key":"2020021217553959200_REF9","doi-asserted-by":"crossref","unstructured":"Guedez L, Courtemanch L, Stetler-Stevenson M. Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood.1998;92: 1342-1349.","DOI":"10.1182\/blood.V92.4.1342"},{"key":"2020021217553959200_REF10","doi-asserted-by":"crossref","unstructured":"Guedez L, Mansoor A, Birkedal-Hansen B, et al. Tissue inhibitor of metalloproteinases 1 regulation of interleukin-10 in B-cell differentiation and lymphomagenesis. Blood.2001;97: 1796-1802.","DOI":"10.1182\/blood.V97.6.1796"},{"key":"2020021217553959200_REF11","doi-asserted-by":"crossref","unstructured":"Angelin-Duclos C, Cattoretti G, Lin KI, Calame K. Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo. J Immunol.2000;165: 5462-5471.","DOI":"10.4049\/jimmunol.165.10.5462"},{"key":"2020021217553959200_REF12","doi-asserted-by":"crossref","unstructured":"Kee BL, Murre C. Transcription factor regulation of B lineage commitment. Curr Opin Immunol.2001;13: 180-185.","DOI":"10.1016\/S0952-7915(00)00202-8"},{"key":"2020021217553959200_REF13","doi-asserted-by":"crossref","unstructured":"O'Connor BP, Gleeson MW, Noelle RJ, Erickson LD. The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease. Immunol Rev.2003;194: 61-76.","DOI":"10.1034\/j.1600-065X.2003.00055.x"},{"key":"2020021217553959200_","doi-asserted-by":"crossref","unstructured":"Chen-Kiang S. Plasma cells and multiple myeloma. Immunol Rev.2003;194: 5-7.","DOI":"10.1034\/j.1600-065X.2003.00062.x"},{"key":"2020021217553959200_","doi-asserted-by":"crossref","unstructured":"Hideshima T, Richardson P, Anderson KC. Novel therapeutic approaches for multiple myeloma. Immunol Rev.2003;194: 164-176.","DOI":"10.1034\/j.1600-065X.2003.00053.x"},{"key":"2020021217553959200_","doi-asserted-by":"crossref","unstructured":"Kyle RA, Rajkumar SV. Monoclonal gammopathies of undetermined significance: a review. Immunol Rev.2003;194: 112-139.","DOI":"10.1034\/j.1600-065X.2003.00056.x"},{"key":"2020021217553959200_REF17","doi-asserted-by":"crossref","unstructured":"Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood.2002;99: 1745-1757.","DOI":"10.1182\/blood.V99.5.1745"},{"key":"2020021217553959200_REF18","doi-asserted-by":"crossref","unstructured":"Lin KI, Lin Y, Calame K. Repression of c-myc is necessary but not sufficient for terminal differentiation of B lymphocytes in vitro. Mol Cell Biol.2000;20: 8684-8695.","DOI":"10.1128\/MCB.20.23.8684-8695.2000"},{"key":"2020021217553959200_REF19","unstructured":"Niller HH, Salamon D, Ilg K, et al. The in vivo binding site for oncoprotein c-Myc in the promoter for Epstein-Barr virus (EBV) encoding RNA (EBER) 1 suggests a specific role for EBV in lymphomagenesis. Med Sci Monit.2003;9: HY1-9."},{"key":"2020021217553959200_REF20","doi-asserted-by":"crossref","unstructured":"Chatterjee M, Honemann D, Lentzsch S, et al. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6\/gp130\/STAT3 pathway. Blood.2002; 100: 3311-3318.","DOI":"10.1182\/blood-2002-01-0102"},{"key":"2020021217553959200_REF21","doi-asserted-by":"crossref","unstructured":"Best CJ, Leiva IM, Chuaqui RF, et al. Molecular differentiation of high- and moderate-grade human prostate cancer by cDNA microarray analysis. Diagn Mol Pathol.2003;12: 63-70.","DOI":"10.1097\/00019606-200306000-00001"},{"key":"2020021217553959200_REF22","doi-asserted-by":"crossref","unstructured":"Rafi A, Nagarkatti M, Nagarkatti PS. Hyaluronate-CD44 interactions can induce murine B-cell activation. Blood.1997;89: 2901-2908.","DOI":"10.1182\/blood.V89.8.2901"},{"key":"2020021217553959200_REF23","unstructured":"Miettinen M. CD30 distribution. Immunohistochemical study on formaldehyde-fixed, paraffin-embedded Hodgkin's and non-Hodgkin's lymphomas. Arch Pathol Lab Med.1992;116: 1197-1201."},{"key":"2020021217553959200_REF24","doi-asserted-by":"crossref","unstructured":"Reimold AM, Iwakoshi NN, Manis J, et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature.2001;412: 300-307.","DOI":"10.1038\/35085509"},{"key":"2020021217553959200_REF25","doi-asserted-by":"crossref","unstructured":"Shaffer AL, Lin KI, Kuo TC, et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity.2002;17: 51-62.","DOI":"10.1016\/S1074-7613(02)00335-7"},{"key":"2020021217553959200_REF26","doi-asserted-by":"crossref","unstructured":"Iwakoshi NN, Lee AH, Vallabhajosyula P, Otipoby KL, Rajewsky K, Glimcher LH. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol.2003;4: 321-329.","DOI":"10.1038\/ni907"},{"key":"2020021217553959200_REF27","doi-asserted-by":"crossref","unstructured":"Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A.2003;100: 9946-9951.","DOI":"10.1073\/pnas.1334037100"},{"key":"2020021217553959200_REF28","doi-asserted-by":"crossref","unstructured":"Rane SG, Reddy EP. JAKs, STATs and Src kinases in hematopoiesis. Oncogene.2002;21: 3334-3358.","DOI":"10.1038\/sj.onc.1205398"},{"key":"2020021217553959200_REF29","doi-asserted-by":"crossref","unstructured":"Lang R, Pauleau AL, Parganas E, et al. SOCS3 regulates the plasticity of gp130 signaling. Nat Immunol.2003;4: 546-550.","DOI":"10.1038\/ni932"},{"key":"2020021217553959200_","doi-asserted-by":"crossref","unstructured":"Donnelly RP, Dickensheets H, Finbloom DS. The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J Interferon Cytokine Res.1999;19: 563-573.","DOI":"10.1089\/107999099313695"},{"key":"2020021217553959200_REF31","doi-asserted-by":"crossref","unstructured":"Choe J, Choi YS. IL-10 interrupts memory B cell expansion in the germinal center by inducing differentiation into plasma cells. Eur J Immunol.1998;28: 508-515.","DOI":"10.1002\/(SICI)1521-4141(199802)28:02<508::AID-IMMU508>3.0.CO;2-I"},{"key":"2020021217553959200_REF32","doi-asserted-by":"crossref","unstructured":"Teramoto N, Pokrovskaja K, Szekely L, et al. Expression of cyclin D2 and D3 in lymphoid lesions. Int J Cancer.1999;81: 543-550.","DOI":"10.1002\/(SICI)1097-0215(19990517)81:4<543::AID-IJC7>3.0.CO;2-3"},{"key":"2020021217553959200_REF33","doi-asserted-by":"crossref","unstructured":"Calame KL, Lin KI, Tunyaplin C. Regulatory mechanisms that determine the development and function of plasma cells. Annu Rev Immunol.2003;21: 205-230.","DOI":"10.1146\/annurev.immunol.21.120601.141138"},{"key":"2020021217553959200_REF34","doi-asserted-by":"crossref","unstructured":"Oelmann E, Herbst H, Zuhlsdorf M, et al. Tissue inhibitor of metalloproteinase 1 is an autocrine and paracrine survival factor, with additional immune-regulatory functions, expressed by Hodgkin\/Reed-Sternberg cells. Blood.2002;99: 258-267.","DOI":"10.1182\/blood.V99.1.258"},{"key":"2020021217553959200_REF35","doi-asserted-by":"crossref","unstructured":"Soro PG, Morales AP, Martinez MJ, et al. Differential involvement of the transcription factor Blimp-1 in T cell-independent and -dependent B cell differentiation to plasma cells. J Immunol.1999;163: 611-617.","DOI":"10.4049\/jimmunol.163.2.611"},{"key":"2020021217553959200_REF36","doi-asserted-by":"crossref","unstructured":"O'Connor BP, Cascalho M, Noelle RJ. Short-lived and long-lived bone marrow plasma cells are derived from a novel precursor population. J Exp Med.2002;195: 737-745.","DOI":"10.1084\/jem.20011626"},{"key":"2020021217553959200_REF37","doi-asserted-by":"crossref","unstructured":"Bergsagel PL, Kuehl WM. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev.2003; 194: 96-104.","DOI":"10.1034\/j.1600-065X.2003.00052.x"},{"key":"2020021217553959200_REF38","doi-asserted-by":"crossref","unstructured":"Jansen-Durr P. How viral oncogenes make the cell cycle. Trends Genet.1996;12: 270-275.","DOI":"10.1016\/0168-9525(96)81455-7"},{"key":"2020021217553959200_REF39","doi-asserted-by":"crossref","unstructured":"Tourigny MR, Ursini-Siegel J, Lee H, et al. CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells. Immunity.2002;17: 179-189.","DOI":"10.1016\/S1074-7613(02)00364-3"},{"key":"2020021217553959200_REF40","doi-asserted-by":"crossref","unstructured":"Kulkarni MS, Daggett JL, Bender TP, Kuehl WM, Bergsagel PL, Williams ME. Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis. Leukemia.2002;16: 127-134.","DOI":"10.1038\/sj.leu.2402328"},{"key":"2020021217553959200_REF41","doi-asserted-by":"crossref","unstructured":"Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood.2004;104: 607-618.","DOI":"10.1182\/blood-2004-01-0037"},{"key":"2020021217553959200_","doi-asserted-by":"crossref","unstructured":"de Leval L, Harris NL. Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance. Histopathology.2003;43: 509-528.","DOI":"10.1111\/j.1365-2559.2003.01758.x"},{"key":"2020021217553959200_REF43","doi-asserted-by":"crossref","unstructured":"Carbone A. Emerging pathways in the development of AIDS-related lymphomas. Lancet Oncol.2003;4: 22-29.","DOI":"10.1016\/S1470-2045(03)00957-4"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/4\/1660\/1707244\/zh800405001660.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/4\/1660\/1707244\/zh800405001660.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T14:56:59Z","timestamp":1682780219000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/105\/4\/1660\/20395\/Tissue-inhibitor-of-metalloproteinase-1-TIMP1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,15]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,2,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-04-1385","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,15]]}}}